The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Expanded eligibility for advanced ischemic stroke therapies and the first detailed recommendations pediatric stroke care are ...

This “long overdue” update expands the pools of patients eligible for thrombolysis and thrombectomy, and tackles pediatric ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

TIGERTRIEVER (TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...

Women with a previous history of ischemic stroke have doubled odds of having another ischemic stroke during pregnancy or early postpartum.

When lesion size and location were matched, hemorrhagic stroke produced worse 3 month disability and higher DALYs than ...

While millions obsess over LDL, top cardiologists reveal that a single "sticky" protein marker provides the most accurate ...